Contact Us
For further information about our company and NexoBrid™,
please contact us at:
Global Headquarters
MediWound Ltd.
42 Hayarkon Street,
Yavne, Israel 8122745
Tel: + +972 77 9714100
Fax: +972 77 9714111
e-mail: info@mediwound.com
European Headquarters
Tel: +49 6142 176590
Email: infoeurope@mediwound.com
Germany
Tel: +49 1732983947
Email: infogermany@mediwound.com
Italy
Tel: +39 3440608370
Email: infoitaly@mediwound.com
Spain
Tel: +34 637784546
Email: infospain@mediwound.com
United Kingdom
Tel: +44 7500875318
Email: infounitedkingdom@mediwound.com
Romania
Tel: +40 784345858
Email: inforomania@mediwound.com
Poland
Tel: +48 607370416
Email: infopoland@mediwound.com
For saftey issues
Please contact email: safetymediwound@primevigilance.com
NexoBridTM
MediWound’s innovative drug, NexoBrid™, was approved in December 2012 by EMA via a centralized procedure and was granted orphan indication for removal of eschar in adults with deep partial- and full-thickness thermal burns (also known as debridement)
